Cancer Center Support Grant

癌症中心支持补助金

• 批准号: 10614238
• 负责人: CHARLES S FUCHS
• 金额: $ 32.71万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10614238
• 关键词: Address; Adoptive Cell Transfers; Area; Award; Basic Science; Biological Markers; Biostatistics Shared Resource; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Science; Catchment Area; Charge; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Communication; Communities; Community Outreach; Comprehensive Cancer Center; Development; Direct Costs; Discipline; Dreams; Early Diagnosis; Education; Evaluation; Extramural Activities; Faculty; Fostering; Funding; Future; Genomics; Goals; Grant; Heart; Immunooncology; Incubators; Individual; Infrastructure; Institutes; Institutional Policy; Intervention; Investments; Laboratories; Leadership; Malignant Neoplasms; Medicine; Mission; Patient Selection; Patient-Centered Care; Patients; Phase; Physicians; Population; Population Research; Prevention; Procedures; Process; Recording of previous events; Research; Research Personnel; Resource Sharing; Resources; Science; Scientist; Strategic Planning; Talents; Teacher Professional Development; Technology; Time; Training; Training and Education; Translational Research; Translations; Yale Cancer Center; anticancer research; arm; bench to bedside; cancer care; cancer diagnosis; cancer prevention; cancer therapy; clinical investigation; community engagement; cost effective; design; diversity and equity; experience; health equity; health inequalities; improved; innovation; interdisciplinary collaboration; member; next generation; novel; novel therapeutic intervention; prevent; programs; recruit; research and development; synergism; therapy resistant; translational scientist; treatment trial

OVERALL PROJECT SUMMARY/ABSTRACT! Now in its 43rd year as an NCI-Designated Comprehensive Cancer Center, Yale Cancer Center (YCC) has established a strong tradition of high-impact cancer research and a deep culture of communication and collaboration that unites 286 basic, translational, population, and clinical scientists representing all biomedical disciplines. YCC arms these investigators with a suite of enabling cores and powerful collaborative opportunities and resources. Through intra- and inter-programmatic collaboration, the overarching goals of YCC are to understand and prevent cancer, detect cancer early, and manage cancer treatment more accurately and effectively. The seven Research Programs are the heart of YCC, and each program is led by a basic scientist in partnership with a clinical/translational scientist to foster transdisciplinary research and the advancement of Yale science from the bench to the clinic. In addition, YCC supports and manages Shared Resources that provide unique expertise and enabling technologies that enrich the scope and expedite progress of each Research Program. YCC infrastructure further enables ground-breaking clinical trials that capitalize on Yale science and incorporate novel designs and biomarker assessments to optimize patient selection, define treatment resistance, and inform new therapeutic approaches. Overall cancer funding (direct costs) has increased 51% from $58.2M in 2012 to $88M in 2017, including an increase from $17.8M to $23.5M in NCI funding (direct costs). YCC holds two NCI SPORE grants, a UM1, U10, multiple P01s, numerous multi- investigator R01 grants, and leadership in two SU2C Dream Team awards. Additionally, during the current funding cycle, YCC leveraged $5.9M, reflecting CCSG Developmental Funds and institutional support, to advance new research and collaborations, resulting in $55.6M in new extramural funding - a 9-fold return on investment. During the same period, accrual to interventional treatment trials increased 82%, from 471 to 859, and accruals to early-phase treatment trials (pilot, I, I-II) increased three-fold, now representing 44% of total treatment accruals. No less important, YCC has expanded and invested in initiatives and research that seeks to impact cancer inequities and the needs of our catchment area at an individual, institutional, and policy level. Over the next five years, YCC will continue to develop initiatives and resources to foster innovation, collaboration, excellence and synergy to maximize the impact of Yale’s talent and expertise on the understanding, prevention and treatment of cancer.!

全面的 项目摘要/摘要！ 耶鲁大学癌症中心（YCC）现在是NCI指定的综合癌症中心的第43年 建立了高影响力癌症研究和深厚沟通文化的牢固传统 将286个基本，翻译，人口和临床科学家组成的合作代表所有生物医学 学科。 YCC武装这些调查员，并提供了一套使核心和强大的协作 机会和资源。通过内部和程序间合作，总体目标 YCC将更多地了解和预防癌症，尽早发现癌症并管理癌症治疗 准确有效。七个研究计划是YCC的核心，每个程序都由 基础科学家与临床/转化科学家合作，以培养跨学科研究和 耶鲁大学从替补席到诊所的进步。此外，YCC支持和管理共享 提供独特的专业知识和能够丰富范围并加速的技术的资源 每个研究计划的进展。 YCC基础设施进一步实现了开创性的临床试验 利用耶鲁大学的科学并纳入新颖的设计和生物标志物评估，以优化患者 选择，定义耐药性并告知新的治疗方法。总体癌症资金（直接 费用）从2012年的5820万美元增加到2017年的880万美元，其中包括从1780万美元增加到2350万美元 在NCI资金（直接费用）中。 YCC持有两个NCI孢子补助金，AM1，U10，多个P01 调查员R01赠款和两个SU2C梦想团队奖的领导层。另外，在电流期间 资金周期，YCC利用了590万美元，反映了CCSG的发展基金和机构支持， 提前新的研究和合作，导致了5560万美元的新校外资金 - 回报率9倍 投资。在同一时期，介入治疗试验的准确性增加了82％，从471到859， 并累计对早期治疗试验（PILOT，I，I-II）增加了三倍，现在占总数的44％ 治疗精度。同样重要的是，YCC已扩展并投资于寻求的计划和研究 在个人，机构和政策层面上影响癌症的不平等和我们集水区的需求。 在接下来的五年中，YCC将继续制定倡议和资源以促进创新， 合作，出色和协同作用，以最大程度地发挥耶鲁大学才华和专家的影响 了解癌症的理解，预防和治疗。